Favorable Rates of Cardiovascular Events with Stringent Cardiovascular Monitoring & a Lowered Dose of Ponatinib as Second-Line Treatment in Chronic Phase CML Patients Failing or Intolerant to First-Line 2nd-Generation TKI treatment: Results of PONS Trial
Le Coutre P. et al. Acta Haematol, May 2025
Favourable rates of cardiovascular events with stringent cardiovascular monitoring and a lowered dose of ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients failing or intolerant to first-line second-generation tyrosine kinase inhibitor treatment: Results of the prospective PONS Trial